ZA200506728B - Improve radiometal complex compositions - Google Patents
Improve radiometal complex compositions Download PDFInfo
- Publication number
- ZA200506728B ZA200506728B ZA200506728A ZA200506728A ZA200506728B ZA 200506728 B ZA200506728 B ZA 200506728B ZA 200506728 A ZA200506728 A ZA 200506728A ZA 200506728 A ZA200506728 A ZA 200506728A ZA 200506728 B ZA200506728 B ZA 200506728B
- Authority
- ZA
- South Africa
- Prior art keywords
- radiopharmaceutical
- composition
- tropane
- radioprotectant
- stabilised
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000002738 chelating agent Substances 0.000 claims abstract description 39
- 229940124553 radioprotectant Drugs 0.000 claims abstract description 32
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 25
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 25
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 25
- 150000004696 coordination complex Chemical class 0.000 claims abstract description 22
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052713 technetium Inorganic materials 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229910052702 rhenium Inorganic materials 0.000 claims abstract description 14
- 230000007935 neutral effect Effects 0.000 claims abstract description 7
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 34
- 229930004006 tropane Natural products 0.000 claims description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 230000002285 radioactive effect Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 11
- 125000005647 linker group Chemical group 0.000 claims description 11
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 9
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002059 diagnostic imaging Methods 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- OJSLUXYIIKQTPB-KGLIPLIRSA-N (1r,5s)-8-methyl-5-phenyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@]23CC[C@@](CCC2)(N3C)[H])=CC=CC=C1 OJSLUXYIIKQTPB-KGLIPLIRSA-N 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229960005219 gentisic acid Drugs 0.000 claims description 2
- 125000005549 heteroarylene group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- -1 rhenium metal complex Chemical class 0.000 abstract description 8
- 239000003446 ligand Substances 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 8
- 230000001588 bifunctional effect Effects 0.000 description 8
- 150000003573 thiols Chemical group 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HZLFSOZSLFKJKA-JSXRDJHFSA-N 2-[2-[[(1s,3s,4r,5r)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methyl-(2-sulfanylethyl)amino]ethylamino]ethanethiol Chemical compound C1([C@@H]2[C@H](CN(CCS)CCNCCS)[C@H]3CC[C@@H](C2)N3C)=CC=C(Cl)C=C1 HZLFSOZSLFKJKA-JSXRDJHFSA-N 0.000 description 3
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000003608 radiolysis reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241001482237 Pica Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- PUZSUVGRVHEUQO-UHFFFAOYSA-N gentisyl alcohol Chemical compound OCC1=CC(O)=CC=C1O PUZSUVGRVHEUQO-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 150000003281 rhenium Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 229940124557 radiopharmaceutical for brain imaging Drugs 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 229940013123 stannous chloride Drugs 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 229940007163 stannous tartrate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03002809A EP1444990A1 (en) | 2003-02-07 | 2003-02-07 | Improved Radiometal Complex Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200506728B true ZA200506728B (en) | 2006-10-25 |
Family
ID=32605351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200506728A ZA200506728B (en) | 2003-02-07 | 2005-08-22 | Improve radiometal complex compositions |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070020177A1 (https=) |
| EP (2) | EP1444990A1 (https=) |
| JP (2) | JP2006528205A (https=) |
| KR (1) | KR20050103221A (https=) |
| CN (1) | CN100548387C (https=) |
| AT (1) | ATE487498T1 (https=) |
| AU (1) | AU2004210191B2 (https=) |
| BR (1) | BRPI0407056A (https=) |
| CA (1) | CA2514307A1 (https=) |
| DE (1) | DE602004029983D1 (https=) |
| ES (1) | ES2355100T3 (https=) |
| MX (1) | MXPA05008356A (https=) |
| NO (1) | NO20053754L (https=) |
| RU (1) | RU2005123799A (https=) |
| WO (1) | WO2004069285A1 (https=) |
| ZA (1) | ZA200506728B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444990A1 (en) * | 2003-02-07 | 2004-08-11 | Amersham plc | Improved Radiometal Complex Compositions |
| US8741261B2 (en) * | 2003-12-18 | 2014-06-03 | Ge Healthcare Limited | Methods for carbon isotope labeling synthesis by transition metal-promoted carbonylation via isocyanate using azides and carbon-isotope monoxide |
| US7667011B2 (en) | 2004-12-03 | 2010-02-23 | Bengt Langstrom | Method for the use of [11C] carbon monoxide in labeling synthesis of 11C-labelled acids by photo-induced free radical carbonylation |
| GB0428020D0 (en) | 2004-12-22 | 2005-01-26 | Amersham Health As | Stabilisation of radiopharmaceutical precursors |
| ES2386364T3 (es) * | 2005-02-01 | 2012-08-17 | Ge Healthcare Limited | Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcado de compuestos marcados por 11C por carbonilación de radical libre inducida térmicamente |
| US20060217537A1 (en) * | 2005-03-22 | 2006-09-28 | Bengt Langstrom | Methods for carbon isotope labeling synthesis by transition metal-promoted carbonylation via ketene using diazo compounds and carbon-isotope monoxide |
| CA2610252A1 (en) * | 2005-06-14 | 2006-12-21 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| US8273861B2 (en) | 2005-08-31 | 2012-09-25 | Ge Healthcare Limited | Method for the use of [11C] carbon monoxide in labeling synthesis of 11C-labelled ketones by photo-induced free radical carbonylation |
| WO2008056481A1 (en) * | 2006-11-09 | 2008-05-15 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| RU2366434C1 (ru) * | 2007-12-07 | 2009-09-10 | Институт неорганической химии им. А.В. Николаева Сибирского отделения Российской Академии наук | Гексаядерные кластерные комплексы рения на основе радиоактивных изотопов, обладающие противоопухолевыми свойствами |
| GB0922023D0 (en) * | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Preparation of n-monofluoroalkyl compounds |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EP2598175B1 (en) | 2010-07-27 | 2020-05-20 | Serac Healthcare Limited | Radiopharmaceutical compositions |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| JP2016510342A (ja) * | 2013-02-15 | 2016-04-07 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 腫瘍画像化のためのキット |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US20150375901A1 (en) * | 2014-06-30 | 2015-12-31 | Karen J. Orlich | Reusable, eco-friendly container for storing and dispensing food and beverage |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| RU2624237C1 (ru) * | 2016-10-26 | 2017-07-03 | Федеральное государственное бюджетное учреждение "Государственный научный центр Российской Федерации - Федеральный медицинский биофизический центр имени А.И. Бурназяна" | Радиофармацевтическая композиция для радиосиновэктомии и способ ее получения |
| US10478824B2 (en) | 2017-08-21 | 2019-11-19 | Bliss Industries, Llc | System and method for installing hammers |
| US10207274B1 (en) | 2017-08-21 | 2019-02-19 | Roger Young | Non-forged hammermill hammer |
| US12138630B2 (en) | 2017-08-21 | 2024-11-12 | Bliss Industries, Llc | Hammermill hammer |
| USD905136S1 (en) | 2018-03-05 | 2020-12-15 | Bliss Industries, Llc | Hammermill hammer |
| US10610870B2 (en) | 2017-08-21 | 2020-04-07 | Bliss Industries, Llc | Hot and cold forming hammer and method of assembly |
| US10486160B2 (en) | 2017-08-21 | 2019-11-26 | Bliss Industries, Llc | Method of replacing hammers and spacers |
| USD839934S1 (en) | 2017-12-06 | 2019-02-05 | Roger Young | Swing hammer |
| USD861048S1 (en) | 2017-12-06 | 2019-09-24 | Roger Young | Swing hammer |
| USD840447S1 (en) | 2017-12-06 | 2019-02-12 | Roger Young | Swing hammer |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| WO2022156908A1 (en) * | 2021-01-25 | 2022-07-28 | Vrije Universiteit Brussel | Method for preparing a lyophilized composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4364920A (en) * | 1975-04-30 | 1982-12-21 | Medi-Physics, Inc. | Stable diagnostic reagents |
| US4233284A (en) * | 1978-03-31 | 1980-11-11 | The Procter & Gamble Company | Stabilized radiographic scanning agents |
| US4497744A (en) * | 1978-03-31 | 1985-02-05 | Mallinckrodt, Inc. | Gentisic acid salts as radiographic scanning agent stabilizers |
| DE78642T1 (de) * | 1981-10-30 | 1983-10-27 | Amersham International Plc, Amersham, Buckinghamshire | Radiopharmazeutische zubereitung auf grund von technetium-99m und reagenz zur herstellung derselben. |
| US6241963B1 (en) * | 1995-10-19 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Dopamine and serotonin transporter ligands and imaging agents |
| US7105678B2 (en) * | 1995-11-03 | 2006-09-12 | Organix, Inc. | Boat tropanes |
| US6171576B1 (en) | 1995-11-03 | 2001-01-09 | Organix Inc. | Dopamine transporter imaging agent |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US20020111486A1 (en) * | 1999-12-03 | 2002-08-15 | Tamagnan Gilles Denis | Transition metal-cyclopentadienyl-tropane conjugates |
| GB0031592D0 (en) * | 2000-12-28 | 2001-02-07 | Nycomed Amersham Plc | Stabilised radiopharmaceutical compositions |
| FR2833952B1 (fr) | 2001-12-26 | 2004-03-26 | Schering Ag | Derive du tropane, produit de chelation comprenant ce derive de tropane et un metal ou un complexe de metal et radiopharmaceutique |
| EP1444990A1 (en) * | 2003-02-07 | 2004-08-11 | Amersham plc | Improved Radiometal Complex Compositions |
-
2003
- 2003-02-07 EP EP03002809A patent/EP1444990A1/en not_active Withdrawn
-
2004
- 2004-02-09 CA CA002514307A patent/CA2514307A1/en not_active Abandoned
- 2004-02-09 RU RU2005123799/15A patent/RU2005123799A/ru not_active Application Discontinuation
- 2004-02-09 US US10/544,736 patent/US20070020177A1/en not_active Abandoned
- 2004-02-09 BR BR0407056-9A patent/BRPI0407056A/pt not_active IP Right Cessation
- 2004-02-09 CN CNB2004800091645A patent/CN100548387C/zh not_active Expired - Lifetime
- 2004-02-09 KR KR1020057014518A patent/KR20050103221A/ko not_active Withdrawn
- 2004-02-09 AT AT04709267T patent/ATE487498T1/de not_active IP Right Cessation
- 2004-02-09 MX MXPA05008356A patent/MXPA05008356A/es unknown
- 2004-02-09 AU AU2004210191A patent/AU2004210191B2/en not_active Ceased
- 2004-02-09 ES ES04709267T patent/ES2355100T3/es not_active Expired - Lifetime
- 2004-02-09 WO PCT/GB2004/000443 patent/WO2004069285A1/en not_active Ceased
- 2004-02-09 DE DE602004029983T patent/DE602004029983D1/de not_active Expired - Lifetime
- 2004-02-09 EP EP04709267A patent/EP1590007B1/en not_active Expired - Lifetime
- 2004-02-09 JP JP2006525001A patent/JP2006528205A/ja active Pending
-
2005
- 2005-08-05 NO NO20053754A patent/NO20053754L/no not_active Application Discontinuation
- 2005-08-22 ZA ZA200506728A patent/ZA200506728B/en unknown
-
2011
- 2011-03-29 JP JP2011071532A patent/JP2011132258A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005123799A (ru) | 2006-03-27 |
| WO2004069285A1 (en) | 2004-08-19 |
| US20070020177A1 (en) | 2007-01-25 |
| JP2011132258A (ja) | 2011-07-07 |
| BRPI0407056A (pt) | 2006-01-17 |
| ATE487498T1 (de) | 2010-11-15 |
| JP2006528205A (ja) | 2006-12-14 |
| EP1590007B1 (en) | 2010-11-10 |
| NO20053754D0 (no) | 2005-08-05 |
| EP1444990A1 (en) | 2004-08-11 |
| MXPA05008356A (es) | 2006-03-13 |
| AU2004210191B2 (en) | 2007-08-23 |
| CN100548387C (zh) | 2009-10-14 |
| KR20050103221A (ko) | 2005-10-27 |
| CA2514307A1 (en) | 2004-08-19 |
| CN1767859A (zh) | 2006-05-03 |
| DE602004029983D1 (de) | 2010-12-23 |
| NO20053754L (no) | 2005-10-05 |
| AU2004210191A1 (en) | 2004-08-19 |
| ES2355100T3 (es) | 2011-03-22 |
| EP1590007A1 (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200506728B (en) | Improve radiometal complex compositions | |
| ES2227621T3 (es) | Liigandos transportadores de dopamina y serotonina y agentes formadores de imagenes. | |
| Kubicek et al. | NOTA complexes with copper (II) and divalent metal ions: kinetic and thermodynamic studies | |
| AU2011214281B2 (en) | Alpha-emitting complexes | |
| IL107560A (en) | Kit for making radiopharmaceutical preparations containing the Technium-M99 complex | |
| US5095111A (en) | Thiolactone bifunctional chelating agents for diagnostic and therapeutic products | |
| US20080124273A1 (en) | Novel cationic metal complex radiopharmaceuticals | |
| WO1993015770A1 (en) | Radiolabelled peptide compounds | |
| US8278448B2 (en) | Technetium and rhenium complexes | |
| Su et al. | A Novel Amine− Dioxime Chelator for Technetium-99m: Synthesis and Evaluation of 2-Nitroimidazole-Containing Analogues as Markers for Hypoxic Cells | |
| JP6514712B2 (ja) | ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用 | |
| ES2320805T3 (es) | Nanoparticulas radiomarcadas. | |
| Vallabhajosula | Chemistry of Therapeutic Radionuclides | |
| Verbruggen | Bifunctional chelators for technetium-99m | |
| John et al. | Synthesis, characterization and biodistribution of a new hexadentate aminethiol ligand labeled with Tc-99m | |
| WO2012175702A1 (en) | Rimfampicin analogue useful for infection imaging | |
| WO1999040882A2 (en) | STEREOSELECTIVE Tc-99m LIGANDS |